Paolo A. Ascierto, MD, director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses treatment sequencing considerations for patients with advanced BRAF-mutant melanoma, based on findings from the phase 2 SECOMBIT (NCT02631447) and phase 3 DREAMseq (NCT02224781) trials.
Health Professionals
Dr Robert on the Role of Adjuvant Anti–PD-1 Therapy in Resected Stage IIB/C Melanoma
Caroline Robert, MD, PhD, head, Dermatology Unit, Gustave Roussy, discusses the role of adjuvant anti–PD-1 therapy in the treatment of patients with resected stage IIB/C melanoma, highlighting findings from the phase 3 KEYNOTE-716 (NCT03553836) and CheckMate 76K (NCT04099251) trials that have informed treatment decisions in this setting.
Reprogramming Microglia: A Promising Approach Against Melanoma Brain Metastases
Melanoma, recognized as the most aggressive form of skin cancer, poses significant risks when it metastasizes to the brain.
Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes
NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).